ATRA
Price
$15.10
Change
+$0.24 (+1.62%)
Updated
Nov 28 closing price
Capitalization
108.87M
Intraday BUY SELL Signals
NTLA
Price
$8.99
Change
+$0.47 (+5.52%)
Updated
Nov 28 closing price
Capitalization
1.04B
82 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATRA vs NTLA

Header iconATRA vs NTLA Comparison
Open Charts ATRA vs NTLABanner chart's image
Atara Biotherapeutics
Price$15.10
Change+$0.24 (+1.62%)
Volume$17.98K
Capitalization108.87M
Intellia Therapeutics
Price$8.99
Change+$0.47 (+5.52%)
Volume$3.71M
Capitalization1.04B
ATRA vs NTLA Comparison Chart in %
ATRA
Daily Signal:
Gain/Loss:
NTLA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATRA vs. NTLA commentary
Nov 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATRA is a StrongBuy and NTLA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 29, 2025
Stock price -- (ATRA: $15.10 vs. NTLA: $8.99)
Brand notoriety: ATRA and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATRA: 29% vs. NTLA: 43%
Market capitalization -- ATRA: $108.87M vs. NTLA: $1.04B
ATRA [@Biotechnology] is valued at $108.87M. NTLA’s [@Biotechnology] market capitalization is $1.04B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATRA’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • ATRA’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATRA and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATRA’s TA Score shows that 6 TA indicator(s) are bullish while NTLA’s TA Score has 6 bullish TA indicator(s).

  • ATRA’s TA Score: 6 bullish, 4 bearish.
  • NTLA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both ATRA and NTLA are a good buy in the short-term.

Price Growth

ATRA (@Biotechnology) experienced а +10.38% price change this week, while NTLA (@Biotechnology) price change was +9.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.92%. For the same industry, the average monthly price growth was +1.16%, and the average quarterly price growth was +72.91%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (+6.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.04B) has a higher market cap than ATRA($109M). ATRA YTD gains are higher at: 13.449 vs. NTLA (-22.899). ATRA has higher annual earnings (EBITDA): 14.3M vs. NTLA (-501.87M). NTLA has more cash in the bank: 460M vs. ATRA (22.3M). ATRA has less debt than NTLA: ATRA (17.7M) vs NTLA (103M). ATRA has higher revenues than NTLA: ATRA (189M) vs NTLA (52.9M).
ATRANTLAATRA / NTLA
Capitalization109M1.04B10%
EBITDA14.3M-501.87M-3%
Gain YTD13.449-22.899-59%
P/E Ratio5.28N/A-
Revenue189M52.9M357%
Total Cash22.3M460M5%
Total Debt17.7M103M17%
FUNDAMENTALS RATINGS
ATRA vs NTLA: Fundamental Ratings
ATRA
NTLA
OUTLOOK RATING
1..100
1464
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
19
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
4065
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (19) in the Biotechnology industry is somewhat better than the same rating for ATRA (66). This means that NTLA’s stock grew somewhat faster than ATRA’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATRA (100). This means that NTLA’s stock grew similarly to ATRA’s over the last 12 months.

NTLA's SMR Rating (95) in the Biotechnology industry is in the same range as ATRA (100). This means that NTLA’s stock grew similarly to ATRA’s over the last 12 months.

ATRA's Price Growth Rating (40) in the Biotechnology industry is in the same range as NTLA (65). This means that ATRA’s stock grew similarly to NTLA’s over the last 12 months.

ATRA's P/E Growth Rating (97) in the Biotechnology industry is in the same range as NTLA (100). This means that ATRA’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATRANTLA
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 24 days ago
86%
Bearish Trend 9 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATRA
Daily Signal:
Gain/Loss:
NTLA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYLGX111.36N/A
N/A
Rydex S&P 500 Pure Growth A
VSCRX55.39N/A
N/A
Virtus KAR Small-Cap Core R6
PLGAX16.67N/A
N/A
Principal LargeCap Growth I A
HDVVX15.58N/A
N/A
Hartford International Equity R6
GQHPX13.41N/A
N/A
GQG Partners US Quality Value Fund Inv

ATRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATRA has been loosely correlated with PHAT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ATRA jumps, then PHAT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATRA
1D Price
Change %
ATRA100%
+1.62%
PHAT - ATRA
36%
Loosely correlated
+2.97%
INVA - ATRA
33%
Poorly correlated
+0.09%
MOLN - ATRA
31%
Poorly correlated
+0.53%
ZNTL - ATRA
30%
Poorly correlated
-0.69%
JAZZ - ATRA
30%
Poorly correlated
-0.22%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+5.52%
VCYT - NTLA
69%
Closely correlated
-0.78%
BEAM - NTLA
60%
Loosely correlated
+1.20%
CRSP - NTLA
59%
Loosely correlated
+0.32%
AXON - NTLA
55%
Loosely correlated
+1.31%
EDIT - NTLA
49%
Loosely correlated
+0.42%
More